-
公开(公告)号：KR1020110100944A
公开(公告)日：2011-09-15
申请号：KR1020100020044
申请日：2010-03-05
Applicant: 한국화학연구원 , 한국콜마홀딩스 주식회사
IPC: A61K31/675 , A61K9/70 , A61P19/10 , A61P19/00
CPC classification number: A61K31/675 , A61K9/0009 , A61K9/0014 , A61K47/14 , A61K47/183 , A61K47/26
Abstract: 본 발명은 경구 투여 시 생체 내 낮은 흡수율과 위장관 부작용을 나타내는 리세드로네이트에 피부 투과 가속제, 폴리아미노폴리카르복실릭계 킬레이트 첨가제, 또는 이들의 혼합물을 첨가한 조성물로서, 이온토포레시스를 통하여 경피 투여 하는 경우 위장관 부작용을 회피하면서도, 높은 체내 흡수율을 나타낼 수 있는 리세드로네이트 함유 경피 투여용 조성물에 관한 것이다.
-
公开(公告)号：KR1020110000259A
公开(公告)日：2011-01-03
申请号：KR1020090057679
申请日：2009-06-26
Applicant: 한국화학연구원 , 주식회사 중앙백신연구소
IPC: A61K39/39 , A61K31/765 , A61P37/02
CPC classification number: A61K31/765 , A61K9/113 , A61K39/39 , Y10S514/885
Abstract: PURPOSE: An immune enhancer composition containing polymer emulsifier as a stabilizing agent and a vaccine composition containing the same are provided to continuously maintain immunity and to ensure formulation stability. CONSTITUTION: An immune enhancer composition contains oil ingredient, non-ionic emulsifier, aqueous ingredient and polymer emulsifier of A-B-A type block copolymer. A and B are denoted by chemical formula 1 and 2, respectively. The molecular weight of A and B is 500-50,000 each. A polymer emulsifier is contained in 0.1-5.0 weight% based on total weight. The immune enhancer is an emulsion of water-in-oil form. A vaccine composition contains the immune enhancer composition and biologically acceptable amount of immunogenic material.
Abstract translation: 目的：提供含有聚合物乳化剂作为稳定剂的免疫增强剂组合物和含有其的疫苗组合物，以连续地保持免疫力并确保制剂的稳定性。 构成：免疫增强剂组合物含有A-B-A型嵌段共聚物的油成分，非离子乳化剂，水性成分和聚合物乳化剂。 A和B分别由化学式1和2表示。 A和B的分子量分别为500-50,000。 基于总重量，聚合物乳化剂的含量为0.1-5.0重量％。 免疫增强剂是油包水形式的乳液。 疫苗组合物含有免疫增强剂组合物和生物可接受量的免疫原性物质。
-
公开(公告)号：KR1020080101056A
公开(公告)日：2008-11-21
申请号：KR1020070047259
申请日：2007-05-15
Applicant: 한국화학연구원
IPC: A61K9/10 , A61K31/337 , B82B1/00 , B82Y5/00
CPC classification number: A61K9/127 , A61K31/685 , A61K31/688 , A61K47/44 , A61K9/107 , A61K31/337 , A61K2300/00 , B82B1/00 , B82Y5/00
Abstract: A diterpenoid alkaloid group drug solution is provided to become soluble in a water phase at a high concentration without a surfactant harmfulness to human body by including a lipid nano particle, to have a size distribution of a uniform particle and to be used as an injection having a high safety. A diterpenoid alkaloid group drug solution is manufactured by dispersing diterpenoid alkaloid group drug having a solid solution state and lipid nano particles in an aquatic medium. The lipid nano particles are manufactured by dispersing a lipid mixture comprising phospholipid, sterols, cationic lipid or anionic lipid and polyethylene glycol in an organic solvent. A mixing ratio of the phospholipid, the sterols, the cationic lipid or the anionic lipid and the polyethylene glycol is 3 ~ 8 : 2 ~ 6 : 1 ~ 5 : 0 ~ 3.
Abstract translation: 提供二萜类生物碱类药物溶液，通过包含脂质纳米颗粒，高浓度而不会对人体具有表面活性物质的危害而在水相中溶解，具有均匀粒子的粒度分布，并用作具有 安全性高。 通过将具有固溶态的二萜生物碱类药物和脂质纳米颗粒分散在水性介质中制备二萜类生物碱类药物溶液。 通过将包含磷脂，固醇，阳离子脂质或阴离子脂质和聚乙二醇的脂质混合物分散在有机溶剂中来制备脂质纳米颗粒。 磷脂，固醇，阳离子脂质或阴离子脂质和聚乙二醇的混合比为3〜8：2〜6：1〜5：0〜3。
-
公开(公告)号：KR1020080094473A
公开(公告)日：2008-10-23
申请号：KR1020070038959
申请日：2007-04-20
Applicant: 한국화학연구원
CPC classification number: A61K9/1271 , A61K9/1277 , A61K9/5123 , A61K9/5146 , A61K31/7048
Abstract: An anionic lipid nanosphere is provided to show increased encapsulation efficiency of an insoluble drug in an aqueous phase by introducing a polyethylene glycol(PEG) containing polyol onto the surface of particles formed from an anionic phospholipid, reduce toxicity of the drug against normal cells and increase in vivo circulation time of the drug by encapsulating a very strongly toxic drug into lipid nanosphere. An anionic lipid nanosphere for encapsulating an insoluble drug such as amphotericin B is characterized in that a PEG containing polymer is coated on the surface of particles formed by an anionic phospholipid. A method for preparing the anionic lipid nanosphere comprises the steps of: (a) mixing 100 parts by weight of lipid prepared by mixing phosphatidylcholine, anionic phospholipd and sterol in a weight ratio of 40-70:5-20:10-40 with 10-30 parts by weight of the polymer containing the PEG and dissolving a mixture in an organic solvent to prepare a lipid-PEG mixture solution; (b) dissolving an insoluble drug in C1-6 linear or branched alcohol to prepare a drug solution; (c) mixing the lipid-PEG mixture solution with the drug solution in a volumetric ratio of 1:1-1:9 to prepare a lipid-PEG-drug mixture solution; (d) dispersing the mixture solution into an aqueous phase in a volumetric ratio of 2:1-10:1 to form lipid nanosphere; and (e) after subjecting the lipid nanosphere solution obtained from the step(d) to distillation at a temperature of 20-50 deg.C under reduced pressure to remove the organic solvent therefrom, filtering it to prepare the anionic lipid nanosphere encapsulating the drug.
Abstract translation: 提供阴离子脂质纳米球，通过将含有聚乙二醇（PEG）的多元醇引入到由阴离子磷脂形成的颗粒表面上，在水相中显示不溶性药物的包封效率，降低药物对正常细胞的毒性并增加 药物的体内循环时间通过将非常强毒性的药物包封在脂质纳米球中。 用于包封不溶性药物如两性霉素B的阴离子脂质纳米球的特征在于将含PEG聚合物涂覆在由阴离子磷脂形成的颗粒的表面上。 制备阴离子脂质纳米球的方法包括以下步骤：（a）将100重量份通过将磷脂酰胆碱，阴离子磷脂和甾醇以40-70:5-20:10-40的重量比混合制备的脂质与10 -30重量份含有PEG的聚合物，并将混合物溶解在有机溶剂中以制备脂质-PEG混合溶液; （b）将不溶性药物溶解在C1-6直链或支链醇中以制备药物溶液; （c）以1：1-1：9的体积比混合脂质-PEG混合溶液与药液，制备脂质-PEG-药物混合溶液; （d）将混合溶液以2:1-10:1的体积比分散在水相中以形成脂质纳米球; 和（e）在将步骤（d）获得的脂质纳米圈溶液在20-50℃的温度下减压蒸馏除去有机溶剂之后，过滤以制备包封该药物的阴离子脂质纳米球 。
-
公开(公告)号：KR100634381B1
公开(公告)日：2006-10-16
申请号：KR1020050112495
申请日：2005-11-23
Applicant: 한국화학연구원
Abstract: Provided are a polysuccinimide-based polymer which shows excellent polymer particle size control, biodegradability and contrast effect when nanoparticles are formed, and a contrast agent containing the polymer. The polysuccinimide-based polymer comprises a main chain having a molecular weight of 1,000-100,000; and a side chain which comprises a hydrophilic group having a molecular weight of 100-20,000 derived from D-lysine, L-lysine, D,L-lysine, polylysine, polyethylene glycol, poly(vinyl pyrrolidone), dextran, polyethylene oxide or poly(vinyl alcohol), a hydrophobic group derived from a C3-C80 amine or phospholipid, and a chelating group where a contrast agent selected from gadolinium, manganese, iron oxide, aluminum, silicon, barium, yttrium and rare earth elements is trapped.
Abstract translation: 本发明提供一种聚琥珀酰亚胺系聚合物和含有该聚合物的造影剂，其显示出优异的聚合物粒径控制，生物降解性和造影效果。 基于聚琥珀酰亚胺的聚合物包含分子量为1,000-100,000的主链; 和包含衍生自D-赖氨酸，L-赖氨酸，D，L-赖氨酸，聚赖氨酸，聚乙二醇，聚（乙烯基吡咯烷酮），葡聚糖，聚环氧乙烷或聚（乙烯吡咯烷酮）的分子量为100-20,000的亲水基团的侧链 （乙烯醇），衍生自C3-C80胺或磷脂的疏水性基团和选自钆，锰，氧化铁，铝，硅，钡，钇和稀土元素的造影剂被捕获的螯合基团。
-
Patent Agency Ranking
公开(公告)号：KR1020060099740A
公开(公告)日：2006-09-20
申请号：KR1020050021150
申请日：2005-03-14
Applicant: 한국화학연구원
CPC classification number: B82Y5/00 , A61K49/1854
Abstract: 본 발명은 수용성 산화철 나노 입자 및 이의 제조방법에 관한 것으로서, 더욱 상세하게는 산화철 전구체의 열분해법을 이용하여 정맥내 투여가 가능한 생체 적합적 고분자인 폴리비닐피롤리돈을 산화철 나노 입자 표면에 코팅함으로써 입자 크기를 제어할 수 있고 물에 잘 녹는 균일한 크기의 산화철 나노 입자를 제조하는 방법과 폴리비닐피롤리돈이 코팅된 수용성 산화철 나노 입자에 관한 것이다. 상기 수용성 산화철 나노 입자는 뛰어난 조영 효과를 가짐으로써 MRI 조영제로서 활용이 가능하다.
산화철, 나노 입자, 산화철 전구체, 열분해법, 폴리비닐피롤리돈, 코팅, MRI 조영제-
公开(公告)号：KR100524700B1
公开(公告)日：2005-10-31
申请号：KR1020030050351
申请日：2003-07-22
Applicant: 한국화학연구원
Abstract: 본 발명은 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용 약제 조성물에 관한 것으로서, 더욱 상세하게는 소수성 및 결정성이 큰 난용성의 고지혈증치료제의 생체 이용률을 향상시키기 위하여 스타틴류의 고지혈증 치료제 활성성분에 소정의 계면활성제와 용해제, 공계면활성제 및 제제의 안정성을 향상시키기 위해 항산화제를 배합 처방하여 나노에멀젼농축액을 제조하여 약물을 인체에 투여하였을 때 소화액 또는 체액에 의해 나노에멀젼을 형성하여 약물의 생체흡수성을 크게 개선시키고 장기보관시 활성성분이 산화되어 산으로 되는 것을 방지하여 안정성을 개선시킨 자가미세유화형 약물전달시스템을 이용한 고지혈증치료용 약제 조성물에 관한 것이다.
-
18.发明公开
公开(公告)号：KR1020050020179A
公开(公告)日：2005-03-04
申请号：KR1020030057918
申请日：2003-08-21
Applicant: 한국화학연구원
IPC: A61K9/00
CPC classification number: A61K9/5042 , A61K9/5026 , A61K31/4422
Abstract: PURPOSE: A composition for producing sustained-release porous membrane for oral drug delivery system and the oral drug delivery system using the same sustained-release porous membrane are provided, which oral drug delivery system controllably and continuously releases drugs, reduces the coating cost by using a smaller amount of porous membrane, and has improved storage stability against humidity and temperature. CONSTITUTION: The composition for producing sustained-release porous membrane for oral drug delivery system comprises one or more film forming materials selected from cellulose-based compound, polymethacrylate, semipermeable polyamide and semipermeable sulfonated polystyrene; the film forming material comprises cellulose acetate and polymethylmethacrylate in a weight ratio of 2 -3:1-1.5. The oral drug delivery system comprises 0.1 to 50 parts by weight of a core containing pharmaceutical active components; and the sustained-release porous membrane containing one or more film forming materials selected from cellulose-based compound, polymethacrylate, semipermeable polyamide, semipermeable polyurethane and semipermeable sulfonated polystyrene.
Abstract translation: 目的：提供一种用于口服药物递送系统的缓释多孔膜的制造用组合物和使用该缓释多孔膜的口服药物输送系统，该口服药物输送系统可控地连续地释放药物，通过使用 少量的多孔膜，并且改善了对湿度和温度的储存稳定性。 构成：用于制备口服药物递送系统的缓释多孔膜的组合物包含一种或多种选自纤维素类化合物，聚甲基丙烯酸酯，半透性聚酰胺和半透性磺化聚苯乙烯的成膜材料; 该成膜材料包括重量比为2-3：1-1.5的乙酸纤维素和聚甲基丙烯酸甲酯。 口服药物递送系统包含0.1至50重量份的含有药物活性组分的核心; 以及含有一种或多种选自纤维素类化合物，聚甲基丙烯酸酯，半透性聚酰胺，半透性聚氨酯和半透性磺化聚苯乙烯的成膜材料的缓释多孔膜。
-
公开(公告)号：KR1020040098746A
公开(公告)日：2004-11-26
申请号：KR1020030030982
申请日：2003-05-15
Applicant: 한국화학연구원
IPC: A61K47/30
CPC classification number: A61K9/0024 , A61K9/1629
Abstract: PURPOSE: Provided is a controlled drug delivery system of a locally implantable agent which controls an initial release speed and duration of drug by adding a biodegradable polymer as a carrier and its monomers to reduce toxicity due to drug-overadministration and other adverse side effects. CONSTITUTION: The controlled drug delivery system of a locally implantable agent is characterized by including or dispersing an effective amount of drug in a mixture of 20-99 wt.% of a biodegradable polymer as a carrier and 1-80 wt.% of its monomers.
Abstract translation: 目的：提供一种局部植入药物的受控药物递送系统，其通过添加可生物降解的聚合物作为载体和其单体来控制药物的初始释放速度和持续时间，以减少由于药物过量给药引起的毒性和其他不良副作用。 构成：本地可植入药物的受控药物递送系统的特征在于将有效量的药物包含或分散在20-99重量％的可生物降解的聚合物作为载体和1-80重量％的单体的混合物中 。
-
公开(公告)号：KR1020040026374A
公开(公告)日：2004-03-31
申请号：KR1020020057820
申请日：2002-09-24
Applicant: 한국화학연구원
IPC: A61K9/16
CPC classification number: A61K9/5026 , A61K9/5047 , A61K31/4045 , A61K47/32 , A61K47/38
Abstract: PURPOSE: Provided is a targeting drug delivery system containing melatonin by using multi-coating methods, thereby effectively regulating the speed of melatonin release. CONSTITUTION: In a targeting drug delivery system containing melatonin, it is characterized by consisting of a crystalline core(1), a coating layer(2) fixed to the outer surface of the crystalline core, an active ingredient layer(3) fixed to the outer surface of the coating layer, a sustained release layer(4) fixed to the outer surface of the active ingredient layer, and an enteric soluble layer(5) fixed to the outer surface of the sustained release layer.
Abstract translation: 目的：提供使用多重涂层方法含有褪黑激素的靶向药物递送系统，从而有效调节褪黑素释放的速度。 构成：在含有褪黑激素的靶向药物递送系统中，其特征在于由结晶核心（1），固定在结晶核心的外表面的涂层（2），固定到结晶核心的活性成分层 涂层的外表面，固定到活性成分层的外表面的缓释层（4）和固定在缓释层的外表面的肠溶性层（5）。
-
-
-
-
-
-
-
-
-
Search Results
127
records
(took 0.028 seconds)
